Evidence map›Paper›PMID 21624135›Full record

ArticleMolecular cancer2011

Histone deacetylase turnover and recovery in sulforaphane-treated colon cancer cells: competing actions of 14-3-3 and Pin1 in HDAC3/SMRT corepressor complex dissociation/reassembly.

Praveen Rajendran, Barbara Delage, W Mohaiza Dashwood, Tian-Wei Yu, Bradyn Wuth, David E Williams, Emily Ho, Roderick H Dashwood

Open access · goldAbstract read
In one paragraph

Article in Molecular cancer, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 75 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
75citing papers in PubMed, 1 pooled it
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

75 citing papers in PubMed, 1 synthesis or guideline pooled it, 123 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Hydrogen Sulfide Biology and Its Role in Cancer.Molecules (Basel, Switzerland) · 2022
    Review
  18. Article
  19. Article
  20. Review

15 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Praveen RajendranLinus Pauling Institute, Oregon State University, Corvallis, OR 97331-6512, USA.
Barbara Delage
W Mohaiza Dashwood
Tian-Wei Yu
Bradyn Wuth
David E Williams
Emily Ho
Roderick H Dashwood
Oregon State University · US

Funding

Transplacental Chemoprevention of Lung Tumors and LymphomasP01CA090890 · NCI · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI DASHWOOD, RODERICK H · 2003 to 2014
$14.2M
MODE OF ACTION OF ENVIRONMENTAL TOXICANTST32ES007060 · NIEHS · OREGON STATE UNIVERSITY · PI Jamie DeWitt, Siva Kumar Kolluri · 1985 to 2026
$11.6M
Dietary HDAC Inhibitors in Colon Cancer PreventionR01CA122959 · NCI · TEXAS A&M UNIVERSITY HEALTH SCIENCE CTR · PI DASHWOOD, RODERICK H · 2008 to 2023
$4.3M
Dietary histone deactylase inhibitors in prostate cancer preventionR01CA122906 · NCI · OREGON STATE UNIVERSITY · PI HO, EMILY · 2007 to 2011
$2.0M
Modulation of Colon Carcinogenesis by ChlorophyllinR01CA065525 · NCI · OREGON STATE UNIVERSITY · PI DASHWOOD, RODERICK H · 2004 to 2008
$1.5M
BETA CATENIN MUTATION IN PHIP AND IQ INDUCED COLON CAR01CA080176 · NCI · OREGON STATE UNIVERSITY · PI DASHWOOD, RODERICK H · 2000 to 2004
$1.3M
MODULATION OF COLON CARCINOGENESIS BY CHLOROPHYLLINR29CA065525 · NCI · UNIVERSITY OF HAWAII AT MANOA · PI DASHWOOD, RODERICK H · 1996 to 2000
$99k
NCI NIH HHS CA090890NCI NIH HHS CA122906NCI NIH HHS CA122959NCI NIH HHS CA65525NCI NIH HHS CA80176NCI NIH HHS P01 CA090890NCI NIH HHS R01 CA122959NIEHS NIH HHS T32 ES007060
6 · The paper itself

Abstract

backgroundHistone deacetylase (HDAC) inhibitors are currently undergoing clinical evaluation as anti-cancer agents. Dietary constituents share certain properties of HDAC inhibitor drugs, including the ability to induce global histone acetylation, turn-on epigenetically-silenced genes, and trigger cell cycle arrest, apoptosis, or differentiation in cancer cells. One such example is sulforaphane (SFN), an isothiocyanate derived from the glucosinolate precursor glucoraphanin, which is abundant in broccoli. Here, we examined the time-course and reversibility of SFN-induced HDAC changes in human colon cancer cells.

resultsCells underwent progressive G2/M arrest over the period 6-72 h after SFN treatment, during which time HDAC activity increased in the vehicle-treated controls but not in SFN-treated cells. There was a time-dependent loss of class I and selected class II HDAC proteins, with HDAC3 depletion detected ahead of other HDACs. Mechanism studies revealed no apparent effect of calpain, proteasome, protease or caspase inhibitors, but HDAC3 was rescued by cycloheximide or actinomycin D treatment. Among the protein partners implicated in the HDAC3 turnover mechanism, silencing mediator for retinoid and thyroid hormone receptors (SMRT) was phosphorylated in the nucleus within 6 h of SFN treatment, as was HDAC3 itself. Co-immunoprecipitation assays revealed SFN-induced dissociation of HDAC3/SMRT complexes coinciding with increased binding of HDAC3 to 14-3-3 and peptidyl-prolyl cis/trans isomerase 1 (Pin1). Pin1 knockdown blocked the SFN-induced loss of HDAC3. Finally, SFN treatment for 6 or 24 h followed by SFN removal from the culture media led to complete recovery of HDAC activity and HDAC protein expression, during which time cells were released from G2/M arrest.

conclusionThe current investigation supports a model in which protein kinase CK2 phosphorylates SMRT and HDAC3 in the nucleus, resulting in dissociation of the corepressor complex and enhanced binding of HDAC3 to 14-3-3 or Pin1. In the cytoplasm, release of HDAC3 from 14-3-3 followed by nuclear import is postulated to compete with a Pin1 pathway that directs HDAC3 for degradation. The latter pathway predominates in colon cancer cells exposed continuously to SFN, whereas the former pathway is likely to be favored when SFN has been removed within 24 h, allowing recovery from cell cycle arrest.

Indexed as

14-3-3 ProteinsAcetylationAnticarcinogenic AgentsApoptosisCaspase 3Cell CycleCell Line, TumorColonic NeoplasmsCycloheximideDactinomycinEnzyme ActivationHCT116 CellsHistone Deacetylase InhibitorsHistone DeacetylasesHumansIsothiocyanates14-3-3 ProteinsAnticarcinogenic AgentsCaspase 3CycloheximideDactinomycinHistone Deacetylase InhibitorsHistone DeacetylasesIsothiocyanatesNCOR2 protein, humanNIMA-Interacting Peptidylprolyl IsomeraseNuclear Receptor Co-Repressor 2Peptidylprolyl IsomerasePIN1 protein, humanProteasome InhibitorssulforaphaneSulfoxidesThiocyanates

Identifiers

PMID21624135
PMCPMC3127849
OpenAlexW2145224778

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.